A new multidistrict litigation over the anti-nausea drug Zofran could be coming to Pennsylvania pending the outcome of a hearing before a federal judicial panel in roughly two weeks.
On Oct. 1, the U.S. Judicial Panel on Multidistrict Litigation is set to consider whether the 12 Zofran cases filed this year from across the country should be consolidated in the U.S. District Court for the Eastern District of Pennsylvania.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
